Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H17N3O |
| Molecular Weight | 219.2829 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)C1=CC(C#N)=C(N)C=C1
InChI
InChIKey=BUXRLJCGHZZYNE-UHFFFAOYSA-N
InChI=1S/C12H17N3O/c1-8(2)15-7-12(16)9-3-4-11(14)10(5-9)6-13/h3-5,8,12,15-16H,7,14H2,1-2H3
| Molecular Formula | C12H17N3O |
| Molecular Weight | 219.2829 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Cimaterol is a chemically stable nonselective agonist β1-, β2-, and β3-adrenoceptors. Cimaterol is used in sport as a stimulant and a fat burner that assists bodybuilders and strength athletes to get rid of body fats. Aside from shedding off fats, another benefit for using cimaterol for athletes is a boost in strength as well as an increase in muscle size or lean body mass. The increase in muscle size has been seen in previous animal studies when cimaterol is used. However, the reason behind the muscle gain is not identified yet, but the body has a very different response compared from taking in anabolic steroids. Experts in the field are saying that the increased nitrogen retention, that is known to cause by cimaterol, maybe the reason behind the muscle gain. Another great thing about Cimaterol is that, it can improve blood flow.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P13945 Gene ID: 155.0 Gene Symbol: ADRB3 Target Organism: Homo sapiens (Human) |
6.62 null [pEC50] | ||
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) |
8.13 null [pEC50] | ||
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) |
8.78 null [pEC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. | 2010-11-30 |
|
| [Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010-08 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010-04 |
|
| Protein microarray: sensitive and effective immunodetection for drug residues. | 2010-02-16 |
|
| Regression-based approach for testing the association between multi-region haplotype configuration and complex trait. | 2009-09-17 |
|
| Evaluation of the illegal use of clenbuterol in Portuguese cattle farms from drinking water, urine, hair and feed samples. | 2009-06 |
|
| Validation of radioimmunoassay screening methods for beta-agonists in bovine liver according to Commission Decision 2002/657/EC. | 2008-12 |
|
| [Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry]. | 2008-11 |
|
| Steroid and beta-adrenergic receptor modifications in target organs of broiler chickens fed with a diet containing beta2-adrenergic agents. | 2008-06 |
|
| [Multi-residue analysis of 10 beta2-agonists in animal tissues using gas chromatography-mass spectrometry]. | 2008-01 |
|
| Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. | 2007-08 |
|
| Field-amplified on-line sample stacking for separation and determination of cimaterol, clenbuterol and salbutamol using capillary electrophoresis. | 2006-08-25 |
|
| Evidence for a secondary state of the human beta3-adrenoceptor. | 2005-12 |
|
| Site of action of beta-ligands at the human beta1-adrenoceptor. | 2005-06 |
|
| [Simultaneous determination of cimaterol, clenbuterol and salbutamol in feeds by capillary zone electrophoresis]. | 2005-05 |
|
| Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry. | 2005-03-12 |
|
| Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005-03-12 |
|
| Determination of clenbuterol, salbutamol, and cimaterol in bovine retina by electrospray ionization-liquid chromatography-tandem mass spectrometry. | 2004-04-16 |
|
| Effect of dietary clenbuterol and cimaterol on muscle composition, beta-adrenergic and androgen receptor concentrations in broiler chickens. | 2004-04 |
|
| Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems. | 2002-08 |
Patents
Sample Use Guides
bodybuilders and strength athletes: Both oral and injectable variants are available for cimaterol. The injectable is subcutaneously administered. Effective dosage, based on research and study, is approximately 0.15 milligram per kilogram, for both male and female. With this dosage, users can have beneficial gains from the drug for subcutaneously administered. New users of this drug are advised to start at the low-end of the spectrum to minimize the unbearable or dangerous side effects.
Route of Administration:
Other
H-cAMP accumulation in response to cimaterol in CHO β1 cells, CHO β2 cells, and CHO β3 cells were meacured. Cimaterol stimulated responses were 96.9 ± 1.1% (log EC50 = −8.13 ± 0.03, n = 9), 98.9 ± 1.7% (log EC50 = −8.78 ± 0.06, n = 9), and 89.6 ± 1.9% (log EC50 = −6.62 ± 0.06, n = 9) of the isoprenaline maximum response at the human β1-, β2-, and β3-adrenoceptors, respectively
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:20 GMT 2025
by
admin
on
Mon Mar 31 18:30:20 GMT 2025
|
| Record UNII |
ZPY8VRF0GB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CIMATEROL
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
SUB06276MIG
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
5773
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
C76017
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
2755
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
100000081036
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
m3551
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID2045652
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
54239-37-1
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
C047411
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL1374751
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
ZPY8VRF0GB
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY | |||
|
W-89
Created by
admin on Mon Mar 31 18:30:20 GMT 2025 , Edited by admin on Mon Mar 31 18:30:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
